

MEETING MINUTES

Fifth Meeting of the EU Malaria Fund's
Scientific Advisory Council (SAC)
Videoconference
Wednesday April 22, 2020, 3 PM - 4:35 PM CEST

Participants

Council members, in alphabetic order:

- *denotes non-voting observers to the Scientific Advisory Council
- ** denotes non-voting delegate to the Scientific Advisory Council
 - Dr. Pedro Alonso*, Director of the WHO Global Malaria Programme, World Health Organization.
 - Prof. Dr. Ruth Arnon, The Paul Ehrlich Professor of Immunology, Weizmann Institute of Science. Former President of the Israel Academy of Sciences and Humanities.
 - Dr. David Canovas-Jorda**, Policy Officer at the European Commission's Directorate-General for Research and Innovation.
 - Prof. Dr. Stefan H. E. Kaufmann, Founding Director of the Max Planck Institute for Infection Biology Berlin.
 - Prof. Dr. Myron Max Levine, Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Diseases, University of Maryland.
 - Dr. Michael Makanga, Executive Director of the European & Developing Countries Clinical Trials Partnership (EDCTP).
 - Stefania Salmaso, Former Director of the National Centre of Epidemiology, Surveillance and Health Promotion. Istituto Superiore di Sanità, Roma.
 - Prof. Dr. Marcel Tanner, President of the Swiss Academy of Sciences. Former Director of the Swiss Tropical and Public Health Institute.
 - Prof. Dr. Halidou Tinto, Member of the Scientific Advisory Committee of EDCTP, Head of Clinical Research Unit of Nanoro (CRUN), Burkina Faso.

Apologies:

Dr. N. Regina Rabinovich, ExxonMobil Malaria Scholar in Residence, Harvard T.H.
 Chan School of Public Health, Harvard University.

Non-council members

- Dr. Matthias von Bismarck-Osten, Investitionsbank Berlin.
- Jean-Luc Bodmer, Bill and Melinda Gates Foundation.
- Martin Dastig, Investitionsbank Berlin.
- Torsten Harr, Investitionsbank Berlin.
- Holm Keller, Executive Chairman, kENUP Foundation, as initiator of the Fund.
- Irene Koutra, Manager Innovation & Alternative Financing, European Investment Bank.
- Thorsten Kurtz, Director, kENUP Foundation.
- Anna Lynch, Life Sciences Specialist, European Investment Bank.
- Tobias Mac-Lean, Public Governance Expert, kENUP Foundation.
- Felicitas Riedl, Head of Life Sciences Department, European Investment Bank.
- Nynke Rozema, Project Manager, kENUP Foundation.
- Marcel Rückwald, Project Manager, kENUP Foundation.
- Yu Zhang, New Products and Special Transactions, European Investment Bank.

I. Welcome & Introduction

The Chairman of this meeting, Prof. Dr. Stefan Kaufmann, welcomed all participants to the fifth meeting of the SAC.

There were no comments to the minutes of the meeting held on December 17, 2019 and therefore the minutes were accepted.

All Members indicated that there was no conflict of interest related to any of the projects presented in this meeting.

The Chairman introduced and granted a special welcome to the two new members of the Scientific Advisory Council, who were accepted into the SAC by written procedure:

- Dr. N. Regina Rabinovich, ExxonMobil Malaria Scholar in Residence, Harvard T.H. Chan School of Public Health, Harvard University.
- Prof. Dr. Halidou Tinto, Member of the Scientific Advisory Committee of EDCTP, Head of Clinical Research Unit of Nanoro (CRUN), Burkina Faso. Prof. Tinto briefly introduced himself to the SAC.

II. Consideration of potential inclusion of two additional projects by companies already in the Fund's portfolio

Two of the companies already included in the Fund's portfolio proposed additional secondary exploitations in COVID-19 on their research platforms for inclusion in the portfolio.

- a. Presentation AchilleS Vaccines Srl on mAbCo19 (Dr. Rappuoli)
- b. Presentation Themis Bioscience GmbH on COVAX (Dr. Tauber)

The Members of the Scientific Advisory Council unanimously voted in favor of the inclusion of the COVID-19 exploitations of AchilleS Vaccines Srl and Themis Bioscience GmbH into the portfolio.

- III. Consideration of initial disbursement requests pursued by two companies in Fund's portfolio
 - a. 2020-002 AchilleS Vaccines Srl
 - b. 2020-001 Themis Bioscience GmbH

The Chairs of the SAC prepared the voting templates, which were reviewed by the other members of the SAC. The SAC recommended financing both projects unanimously.